uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted January 12, 2021

FDA Warns Seller of Joint and Hair Loss Products

On December 22, 2020, the FDA issued a warning letter to Speedwinds Nutrition, Inc. following a review of the company's website, which found statements made about the company's products Synotrex and Sephren to be drug claims.

For example, Synotrex was promoted with statements such as "Within a few short days of using Synotrex, you can expect the following benefits: Reduced joint pain, swelling and stiffness... Rebuild worn out and damaged cartilage... Relief of chronic pain... Minimize discomfort from osteoarthritis or injury."

See ConsumerLab's Joint Health Supplements Review (Glucosamine, Chondroitin, MSM and Boswellia) for tests of related products.

Sephren was promoted with statements such as "With Sephren, you can feel confident that Sephren will:... Stop the root causes of... female hair loss."

In addition, the products were found to be misbranded because they do not contain adequate directions for safe use, as required by federal regulations.

For more information, use the link below.

Warning Letter: Speedwinds Nutrition, Inc.

See related warnings:

FDA Warns Seller of Evening Primrose Oil and Beta Glucan

FDA Warns Seller of Curcumin and Cholesterol Supplements

FDA Warns Immusist for Drug Claims

FDA Warns Seller of Digestive Enzymes, Nattokinase, and More

Seller of Cholesterol-Lowering Supplements Warned for Drug Claims